Company Profile
PDS Biotechnology Corporation Stock Price, News & Analysis
- Ticker:
- PDSB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.75 USD (+2.81%)
Close
Last updated: August 6, 2026
64.7M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PDSB closed up 2.81% at $0.7471. No new same-company headline was identified in the current news window.
Company overview
Cancer Immunotherapy Company
PDS Biotechnology develops immunotherapies intended to activate targeted T-cell responses against difficult-to-treat cancers.
Versamune Platform
The Versamune platform is designed to stimulate antigen-specific cytotoxic T cells while overcoming immunosuppressive signaling in the tumor microenvironment.
PDS0101 and PDS01ADC
PDS0101 targets HPV16-positive cancers, while PDS01ADC is an antibody-drug conjugate program being evaluated in metastatic colorectal cancer.
Future catalysts
PDS Biotech is working to restart enrollment in the amended Phase 3 VERSATILE-003 study.
Recent news
- 01
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Source: PDS Biotechnology Corporation
- 02
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
Source: PDS Biotechnology Corporation
- 03
- 04
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Source: PDS Biotechnology Corporation
- 05
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
Source: PDS Biotechnology Corporation
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PDS Biotechnology Corporation (PDSB)?
PDS Biotechnology Corporation (PDSB) most recently closed at 0.75 USD, a +2.81% move versus the previous session.
What is the market cap of PDS Biotechnology Corporation (PDSB)?
PDS Biotechnology Corporation currently has a market capitalization of 64.7M USD on BioPharmSignal.
What does PDS Biotechnology Corporation do?
Cancer Immunotherapy Company PDS Biotechnology develops immunotherapies intended to activate targeted T-cell responses against difficult-to-treat cancers. Versamune Platform The Versamune platform is designed to stimulate antigen-specific cytotoxic T cells while overcoming immunosuppressive signaling in the tumor microenvironment. PDS0101 and...
On which exchange is PDSB stock listed?
PDS Biotechnology Corporation (PDSB) is associated with NASDAQ, United States, Biopharma.
What is VERSATILE-003?
PDS Biotech is working to restart enrollment in the amended Phase 3 VERSATILE-003 study.
Which conditions is PDS Biotechnology Corporation targeting with VERSATILE-003?
PDS Biotechnology Corporation is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does PDS Biotechnology Corporation describe recent progress with VERSATILE-003?
PDS Biotech is working to restart enrollment in the amended Phase 3 VERSATILE-003 study.
What is Cancer?
Cancer Immunotherapy Company PDS Biotechnology develops immunotherapies intended to activate targeted T-cell responses against difficult-to-treat cancers.